RxDoctor Payments Data

Melissa Elder, MD

Pediatric Rheumatology · Gainesville, FLNPI 1659328912

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 6 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Janssen Scientific Affairs, LLC at 35.9% of the total.

$659in general payments, 2019–2025

Across 6 payments — averaging $109.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Scientific Affairs, LLC$237
  • ADMA Biomanufacturing LLC$152
  • Sobi, Inc$150
  • Genentech USA, Inc.$100
  • Novartis$20
$604,109in research payments, 2019–2025

Across 30 payments — averaging $20,137 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Swedish Orphan Biovitrum AB$401K
  • ADMA Biomanufacturing LLC$161K
  • Sanofi US Services Inc.$30K
  • Novartis$13K

What the payments were for

  • Food & beverage$659100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few pediatric rheumatology providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$10,892
Medicare patients
20
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other pediatric rheumatology in Gainesville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →